Flurbiprofen Axetil

Flurbiprofen Axetil (CAS No.: 91503-79-6) is a synthetic small molecule NSAID prodrug widely classified in inflammation and neurobiology research as a nonselective cyclooxygenase inhibitor precursor that is converted to the active flurbiprofen moiety in biological systems, and it is routinely positioned in discovery workflows focused on inflammatory signaling, pain related biology, and disease mechanism studies rather than any human use context; mechanistically, published preclinical evidence indicates modulation of prostaglandin associated COX pathways together with reported effects on MEK ERK, AMPK alpha NF kappa B, and PPAR gamma linked signaling networks, supporting its use as a pharmacological probe for studying pathway cross talk in complex cellular stress and inflammatory states, including oncology and ischemia related experimental paradigms; activity reporting in the literature is commonly pathway and model dependent, and where quantitative enzyme or cellular potency values are not consistently standardized for this prodrug form, its apparent pharmacological effects are generally interpreted within nanomolar to micromolar operational testing windows after consideration of metabolic conversion kinetics and exposure conditions; in vitro and in vivo applications typically include cell based inflammation assays, migration and invasion related cancer cell studies, and rodent models of focal or global cerebral ischemia reperfusion injury and cognitive impairment associated neuroinflammation, with concentrations or doses used in experiments typically depending on specific experimental designs and research objectives, thereby making this compound suitable as a research category tool for mechanism driven screening, target validation support, and comparative profiling against other COX pathway modulators in biomedical and drug discovery settings.